Skip to main content
Journal Article

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy NCT01712061

  • Pfizer
ClinicalTrials.gov (2014) 2015(03.08.2015)
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

PF-04634817, 229 subjects treated for 12 weeks with CCR2/5 inhibitor

Author supplied keywords

Cite

CITATION STYLE

APA

Pfizer. (2014). A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy NCT01712061. ClinicalTrials.Gov, 2015(03.08.2015). Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT01712061

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free